Inhibition of the interaction between PD-1 and PD-L1 (38), or the inhibition of CTLA-4, can activate T cells (39) and enhance the immune attack on pancreatic cancer cells. This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.